Analysts Set MindWalk Holdings Corp. (NASDAQ:HYFT) Target Price at $5.00

by · The Markets Daily

MindWalk Holdings Corp. (NASDAQ:HYFT – Get Free Report) has received an average rating of “Moderate Buy” from the five brokerages that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $5.00.

Several equities research analysts recently commented on the company. HC Wainwright reiterated a “buy” rating on shares of MindWalk in a report on Monday, July 20th. Wall Street Zen cut shares of MindWalk from a “hold” rating to a “sell” rating in a research note on Saturday. JonesTrading assumed coverage on shares of MindWalk in a report on Thursday, April 16th. They set a “buy” rating and a $5.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of MindWalk in a research note on Wednesday, July 15th.

Get Our Latest Stock Analysis on HYFT

Institutional Investors Weigh In On MindWalk

Several institutional investors and hedge funds have recently added to or reduced their stakes in HYFT. Renaissance Technologies LLC raised its stake in MindWalk by 8.4% during the 4th quarter. Renaissance Technologies LLC now owns 239,080 shares of the company’s stock valued at $435,000 after buying an additional 18,600 shares during the last quarter. Bank of Montreal Can boosted its stake in shares of MindWalk by 81.0% in the 4th quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock worth $100,000 after buying an additional 24,500 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of MindWalk in the 4th quarter worth $51,000. XTX Topco Ltd grew its holdings in shares of MindWalk by 118.6% in the fourth quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock worth $149,000 after acquiring an additional 44,331 shares during the period. Finally, Bridgeway Capital Management LLC bought a new stake in shares of MindWalk in the fourth quarter worth $91,000. Hedge funds and other institutional investors own 6.70% of the company’s stock.

MindWalk Trading Up 5.9%

Shares of HYFT opened at $1.44 on Friday. The company’s fifty day simple moving average is $1.56. The company has a current ratio of 2.80, a quick ratio of 2.72 and a debt-to-equity ratio of 0.26. MindWalk has a 12 month low of $0.99 and a 12 month high of $3.25. The stock has a market cap of $67.26 million, a P/E ratio of -6.55 and a beta of 0.83.

MindWalk (NASDAQ:HYFT – Get Free Report) last posted its quarterly earnings results on Wednesday, July 22nd. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The business had revenue of $3.03 million during the quarter. MindWalk had a negative return on equity of 92.61% and a negative net margin of 89.65%. As a group, research analysts forecast that MindWalk will post -0.21 EPS for the current year.

About MindWalk

(Get Free Report)

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.

Further Reading